Articles from Decoy Therapeutics, Inc

Recognition highlights the IMP³ACT™ platform and Designable Multi-Antivirals (D-MAVs), single drugs designed to work across many viruses

Lead pan-coronavirus program expected to file CTA/IND in 2H 2027Optimized lead candidate shows potential for once-weekly dosing in preclinical studiesCash on balance sheet of $8.1 million at September 30, 2026